What is the translation of " BASED ON IN VITRO " in Croatian?

• na temelju in vitro
• na osnovi in vitro

Examples of using Based on in vitro in English and their translations into Croatian

Based on in vitro data, afatinib is a moderate inhibitor of P-gp.
Na osnovi in vitro podataka, afatinib je umjereni P-gp inhibitor.

Such interactions have not been established in vivo but are possible based on in vitro data.
Takve interakcije nisu utvrđene iv vivo, ali su moguće temeljem podataka in vitro.

Based on in vitro results, there is a risk for enzyme induction by tedizolid phosphate.
Na temelju rezultata in vitro, postoji rizik od indukcije enzima tedizolidfosfatom.

Artenimol and piperaquine were not genotoxic/clastogenic based on in vitro and in vivo testing.
Artenimol i piperakin nisu bili genotoksični/klastogeni na temelju in vitro i in vivo ispitivanja.

Based on in vitro studies, osimertinib is a competitive inhibitor of BCRP transporters.
Temeljeno na in vitro ispitivanjima, osimertinib je kompetitivni inhibitor BCRP transportera.

Boceprevir or telaprevir have the potential to adversely affect the intracellular activation and clinical antiviral efficacy of tenofovir alafenamide based on in vitro data.
Boceprevir ili telaprevir mogu štetno djelovati na intracelularnu aktivaciju i kliničku antivirusnu djelotvornost tenofoviralafenamida na temelju in vitro podataka.

Based on in vitro data, ceritinib is a substrate of the efflux transporter P-glycoprotein P-gp.
Na temelju in vitro podataka, ceritinib je supstrat efluksnog transportera P-glikoproteina P-gp.

Neither trifluridine nor tipiracil hydrochloride was an inhibitor of or substrate for human uptake and efflux transporters based on in vitro studies, except for OCT2 and MATE1.
Niti trifluridin niti tipiracilklorid ne inhibiraju ljudske transportne proteine za unos i efluks niti su njihovi supstrati, što se temelji na in vitro ispitivanjima, osim OCT2 i MATE1.

Based on in vitro studies, empagliflozin does not inhibit, inactivate, or induce CYP450 isoforms.
Na temelju in vitro ispitivanja empagliflozin ne inhibira, ne inaktivira niti ne inducira izoforme CYP450.

Conflicting reports in the literature, based on in vitro findings from human tumour samples, suggest erythropoietins may play a role as tumour proliferators.
Proturječna izvješća u literaturi temeljena na in vitro nalazima iz uzoraka tumora u ljudi, navode moguću ulogu eritropoetina kao tumorskih proliferatora.

Based on in vitro data, at clinically relevant concentrations avanafil could be an inhibitor of BCRP.
Na temelju in vitro podataka, avanafil bi, u klinički značajnim koncentracijama, mogao biti inhibitor BCRP-a.

Based on in vitro and animal studies, it appears that Sunifiram powder acts via AMPA-receptor activation.
Na temelju in vitro i animalnih studija, čini se da Sunifirram prah djeluje putem aktivacije AMPA-receptora.

Based on in vitro data pasireotide appears to be a substrate of efflux transporter P-gp P-glycoprotein.
Na temelju in vitro podataka, čini se da je pasireotid supstrat P-gp(P-glikoprotein) transportera za izbacivanje.

Based on in vitro data, ceritinib also inhibits CYP2A6 and CYP2E1 at clinically relevant concentrations.
Na temelju in vitro podataka, ceritinib također inhibira CYP2A6 i CYP2E1 pri klinički relevantnim koncentracijama.

Based on in vitro data, lesinurad may be a mild inducer of CYP2B6 but this interaction has not been studied clinically.
Na temelju in vitro podataka, lesinurad može biti blagi induktor CYP2B6, ali ova interakcija nije klinički ispitana.

Based on in vitro studies, empagliflozin is considered unlikely to cause interactions with drugs that are P-gp substrates.
Na temelju in vitro ispitivanja ne smatra se da empagliflozin izaziva interakcije s lijekovima koji su P-gp supstrati.

Based on in vitro data, ceritinib competitively inhibits the metabolism of a CYP3A substrate, midazolam, and a CYP2C9 substrate, diclofenac.
Na temelju in vitro podataka, ceritinib kompetitivno inhibira metabolizam CYP3A supstrata, midazolama, te CYP2C9 supstrata, diklofenaka.

Based on in vitro data, betaine anhydrous might interact with amino acids mixtures and medicinal products containing vigabatrin and GABA analogues.
Na temelju in vitro podataka, bezvodni betain može ući u interakciju s mješavinama aminokiselina i lijekovima koji sadrže vigabatrin i analoge GABA-e.

Based on in vitro studies, approximately 1% of capsaicin is estimated to be absorbed into the epidermal and dermal layers of skin during one-hour applications.
Na temelju in vitro ispitivanja procijenjeno je da se približno 1% kapsaicina apsorbira u epidermalne i dermalne slojeve kože tijekom jednosatne primjene.

Based on in vitro data, pitolisant and its main metabolites may induce CYP3A4 and CYP2B6 at therapeutic concentrations and by extrapolation, CYP2C, UGTs and P-gp.
Na temelju in vitro podataka, pitolizant i njegovi glavni metaboliti mogu inducirati CYP3A4 i CYP2B6 pri terapijskim koncentracijama i ekstrapolacijom, CYP2C, UGT-ove i P-gp.

Based on in vitro data riociguat and its main metabolite are substrates of the transporter proteins P-gp(P-glycoprotein) and BCRP breast cancer resistance protein.
Na temelju in vitro podataka, riocigvat i njegov glavni metabolit supstrati su transportnih proteina P-gp(P-glikoproteina) i BCRP proteina rezistencije na karcinom dojke.

Based on in vitro studies, osimertinib is a competitive inhibitor of CYP 3A4/5 but not CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6 and 2E1 at clinically relevant concentrations.
Na temelju in vitro ispitivanja, pri klinički relevantnim koncentracijama, osimertinib je kompetitivni inhibitor CYP3A4/5, ali ne i CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6 i 2E1.

Based on in vitro experiments, we have further hypothesized that the reversible redox regulation could be of physiological importance for mammalian dipeptidyl peptidases III.
Nadalje, na osnovi naših in vitro provedenih eksperimenata, pretpostavili smo da bi reverzibilna redoks regulacija mogla biti od fiziološke važnosti zadipeptidil- peptidaze III sisavaca.

Based on in vitro studies utilising human liver enzymes, paliperidone is not a substrate for CYP1A2; smoking should, therefore, not have an effect on the pharmacokinetics of paliperidone.
Temeljem in vitro ispitivanja u kojima su korišteni enzimi ljudske jetre, paliperidon nije supstrat za CYP1A2; pušenje stoga ne bi trebalo utjecati na farmakokinetiku paliperidona.

Based on in vitro studies utilising human liver enzymes, lurasidone is not a substrate for CYP1A2; smoking should, therefore, not have an effect on the pharmacokinetics of lurasidone.
Zasnovano na in vitro ispitivanjima korištenjem ljudskih jetrenih enzima, lurasidon nije supstrat za CYP1A2; stoga pušenje ne bi trebalo utjecati na farmakokinetiku lurasidona.

Based on in vitro studies, ataluren is an inhibitor of UGT1A9, organic anion transporter 1(OAT1), organic anion transporter 3(OAT3) and organic anion transporting polypeptide 1B3 OATP1B3.
Na temelju in vitro ispitivanja, ataluren je inhibitor UGT1A9, prijenosnika organskih aniona 1(OAT1), prijenosnika organskih aniona 3(OAT3) i transportnog polipeptida za organske anione 1B3 OATP1B3.

Based on in vitro data, ibrutinib is a weak reversible inhibitor towards CYP3A4 at the intestinal level and may therefore increase the exposure to CYP3A4 substrates sensitive to gut CYP3A metabolism.
Na temelju in vitro podataka, ibrutinib je slabi reverzibilni inhibitor CYP3A4 na crijevnoj razini i stoga može povećati izloženost supstratima CYP3A4 osjetljivim na crijevni CYP3A metabolizam.

Based on in vitro studies, telaprevir may potentially increase plasma concentrations of medicinal products in which excretion is dependent upon multidrug and toxin extrusion(MATE)-1 and MATE2-K see table 2.
Na temelju in vitro ispitivanja, telaprevir potencijalno može povisiti koncentracije u plazmi lijekova u kojih je izlučivanje ovisno o ekstruziji transportera više lijekova i toksina(MATE)-1 i MATE2-K vidjeti tablicu 2.

Based on in vitro studies, no pharmacokinetic interaction is expected with medicinal products metabolised by the following cytochrome isoenzymes: CYP1A2, CYP2D6, CYP3A4/5, CYP2E1, CYP2C9, CYP2C8, CYP2C19, or CYP2B6.
Na temelju in vitro ispitivanja, ne očekuje se nikakva farmakokinetička interakcija s lijekovima koji se metaboliziraju sljedećim izoenzimima citokroma: CYP1A2, CYP2D6, CYP3A4/5, CYP2E1, CYP2C9, CYP2C8, CYP2C19 ili CYP2B6.

Based on in vitro studies and pharmacokinetic data obtained in healthy volunteers the following table describes interference with laboratory tests that may be observed following a 5 g dose of hydroxocobalamin.
Na temelju in vitro ispitivanja i farmakokinetičkih podataka dobivenih od zdravih dobrovoljaca sljedeća tablica opisuje interferencije s laboratorijskim testovima koje se mogu primijetiti nakon doze hidroksokobalamina od 5 g.